Scenic Biotech's lead compound (NCE) is adressing lysosomal health and prevention of neurodegeneration.

Scenic is developing modifier therapies, a new approach to treating disease. Our lead molecule is an inhibitor of a lysosomal target to treat Lysosomal Storage Disorders and Neurodegeneration.